Skip to main content
AVECHO BIOTECHNOLOGY LIMITED logo

AVECHO BIOTECHNOLOGY LIMITED — Investor Relations & Filings

Ticker · AVE ISIN · AU0000047441 LEI · 529900FA9G9T82C2LV25 ASX Manufacturing
Open in API
Filings indexed 881 across all filing types
Latest filing 2017-08-30 Interim / Quarterly Rep…
Country AU Australia
Listing ASX AVE

About AVECHO BIOTECHNOLOGY LIMITED

https://avecho.com.au/

Avecho Biotechnology Limited develops and commercializes human and animal health products using its proprietary drug delivery system, Tocopheryl Phosphate Mixture (TPM®). Derived from Vitamin E, TPM® is designed to enhance the solubility and absorption of active ingredients through the skin and digestive tract. The company focuses on applying this technology to pharmaceuticals, nutraceuticals, and animal health sectors. A primary area of development includes medicinal cannabis, where Avecho has produced high-bioavailability cannabidiol (CBD) softgel capsules for therapeutic use. The company’s portfolio also includes applications in pain management and dermatology, leveraging TPM® to improve the delivery of poorly soluble molecules and enhance the efficacy of existing treatments.

Recent filings

Filing Released Lang Actions
June 2017 Half-year Financial Report and Appendix 4D 21 pages 404.3KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Phosphagenics Limited Appendix 4D Half Year Report' and covers the half year ended 30 June 2017. It includes detailed financial statements such as the Consolidated Income Statement, Balance Sheet, Statement of Cash Flows, Directors' Report, and Auditor's Review Report. The content includes comprehensive financial data, operational review, and management commentary for the half-year period. The presence of actual financial statements and substantive financial data confirms this is a financial report for a period shorter than a full fiscal year. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2017
2017-08-30 English
Phosphagenics Half Year Financial Results 3 pages 271.7KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Phosphagenics Half Year Financial Results' and reports financial results for the six months ended 30 June 2017. It includes detailed financial data such as net loss after tax, revenue, cash position, expenses, and operational highlights. The document is 8378 characters long, which is substantial and contains actual financial statements and analysis for a period shorter than a full fiscal year. This matches the definition of an Interim / Quarterly Report (IR). It is not merely an announcement of a report or a certification, but a comprehensive financial report for the half year period. H1 2017
2017-08-30 English
Phosphagenics Signs Patch Development Agreement with Terumo 3 pages 120.2KB
Capital/Financing Update Classification · 95% confidence The document is a market announcement from Phosphagenics Limited regarding the signing of a development agreement with Terumo Corporation for a drug delivery patch in Japan. It details the terms of the agreement, development milestones, and strategic decisions. There are no financial statements, quarterly or annual results, or detailed financial data. The content focuses on a business development update related to a partnership and product development progress. This fits the category of Capital/Financing Update (CAP) as it relates to development agreements and potential milestone payments, which are financing-related activities. The document length is 6826 characters, which is sufficient for a detailed announcement but does not constitute a full financial report or earnings release. Therefore, the appropriate classification is CAP with high confidence.
2017-08-21 English
Phosphagenics Sells BioElixia Brand to Pure Beauty Australia 2 pages 120.9KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from Phosphagenics Limited regarding the sale of its BioElixia® Beauty Brand to Pure Beauty Australia. It details the terms of the sale, the strategic rationale, and some background on the companies involved. There are no financial statements, no regulatory certifications, no voting results, no management or board changes, no earnings data, and no mention of any report publication. The content is a corporate transaction announcement related to business operations but not a merger or acquisition filing (which would be more formal and regulatory in nature). It is not a financial report or an investor presentation. This type of document fits best under the category of a general Regulatory Filing (RNS) as it is a regulatory announcement of a material business event that does not fit other more specific categories.
2017-08-09 English
Appendix 3B 9 pages 471.8KB
Capital/Financing Update Classification · 95% confidence The document is an Appendix 3B form, which is a standard ASX (Australian Securities Exchange) form used for announcements related to new issues of securities, applications for quotation of additional securities, and agreements related to these securities. The content includes detailed information about the class of securities issued (2016 and 2017 Options), number of securities, terms, vesting conditions, issue dates, and compliance with ASX rules. It is not a financial report, earnings release, or management discussion, but rather a formal announcement of a capital/financing event involving issuance of options under an employee equity incentive plan. The document is lengthy (over 14,000 characters) and contains substantive details about the securities issuance. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2017-06-04 English
2017 AGM Chairman and CEO Presentations 11 pages 492.6KB
AGM Information Classification · 100% confidence The document is a detailed transcript of speeches and presentations given at the Annual General Meeting (AGM) of Phosphagenics Limited held on 31 May 2017. It includes the Chairman's Address and the CEO's Address, discussing company progress, restructuring, arbitration updates, business strategy, and shareholder questions. The content is typical of AGM materials, focusing on company updates and shareholder communication during the meeting rather than a formal annual report or financial statements. The presence of phrases like 'welcome to the Annual General Meeting' and the detailed narrative of the meeting's proceedings confirm this classification. Therefore, the document fits the category of AGM Information (AGM-R).
2017-05-30 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.